Spineway Stock
-
Your prediction
Spineway Stock
Pros and Cons of Spineway in the next few years
Pros
Cons
Performance of Spineway vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Spineway | - | - | - | - | - | - | - |
| Crossject S.A. | -0.250% | 0.744% | -3.103% | -43.217% | -55.286% | -25.641% | 7.124% |
| Implanet S.A. | 67.770% | 50.498% | 44.728% | -29.658% | 69.981% | -90.650% | -97.565% |
| Visiomed Group | -4.620% | 15.385% | -7.143% | -51.323% | -24.419% | -53.660% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the provided financial statements, the general impression of Spineway is that of a company in the Healthcare Equipment & Supplies industry that has experienced growth in recent years, with some improvements in its financial performance. However, there still remain certain areas of concern that require further attention and analysis to better understand its overall financial health.
Growing total assets: The total assets of Spineway have consistently increased over the past few years, with a significant growth from €12,375,771 in 2019 to €25,247,996 in 2021. This is an indication of the company's ability to expand its business operations and potentially generate higher revenues.
Increasing stockholders' equity: The total stockholder equity has experienced steady growth - from €6,431,048 in 2019 to €21,325,795 in 2021. An increase in stockholders' equity is generally a positive signal as it suggests that the company has been successful in retaining earnings and raising additional capital.